107 filings
Page 4 of 6
8-K
g2puudpfh7p5g0
15 Apr 19
Proteon Therapeutics Announces Review of Potential Strategic Transactions
4:30pm
8-K
z5eqnha27
28 Mar 19
Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas
8:00am
8-K
3r3mc5e1r3
13 Mar 19
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
8:00am
8-K
u5rs77
7 Nov 18
Proteon Therapeutics Announces Third Quarter 2018 Financial Results
8:01am
8-K
04al4mn4e7bt
7 Aug 18
Proteon Therapeutics Announces Second Quarter 2018 Financial Results
8:01am
8-K
1u5kf c0dcr02h8hmgsp
11 Jun 18
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
vtpspqy1m9nfd3v0
9 May 18
Proteon Therapeutics Announces First Quarter 2018 Financial Results
8:10am
8-K
b3s0oh3g z9kn2n64t
8 May 18
Proteon Therapeutics and Lonza Extend Manufacturing Agreement for Commercial Supply
7:10am
8-K
2e8zc
14 Mar 18
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results
12:00am
8-K
b58s7r7bweg
14 Mar 18
Other Events
12:00am
8-K
ss1u3nk03t7xda6g8
5 Mar 18
Proteon Therapeutics Completes Enrollment in PATENCY-2, Phase 3 Clinical Trial of Investigational Vonapanitase
12:00am
8-K
lvrz2i7 1c7w
7 Nov 17
Proteon Therapeutics Announces Third Quarter 2017 Financial Results
12:00am
8-K
syo718 ipa9
22 Aug 17
Entry into a Material Definitive Agreement
12:00am
8-K
b5pmlfyjn2q
7 Aug 17
Proteon Therapeutics Announces Second Quarter 2017 Financial Results
12:00am
8-K
eyla 2xyzewxrp7sez
3 Aug 17
Proteon Therapeutics Announces Closing of $22 Million Convertible Preferred Stock Financing
12:00am
8-K
x495ilpgj x8uugr6ufx
26 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
i3v1 r5zjz
23 Jun 17
Entry into a Material Definitive Agreement
12:00am
8-K
2qr87f5zoe52q7t
22 Jun 17
Proteon Therapeutics Announces $22.0 Million Private Placement
12:00am
8-K
m5sx6 qnllim0uc0
10 May 17
Proteon Therapeutics Announces First Quarter 2017 Financial Results
12:00am
8-K
2j1vdliro91attza
2 May 17
Proteon Therapeutics Announces Increase to Enrollment of Ongoing Phase 3 PATENCY-2 Clinical Trial
12:00am